BR112019002510A2 - peptídeo alvo de tumor maligno - Google Patents
peptídeo alvo de tumor malignoInfo
- Publication number
- BR112019002510A2 BR112019002510A2 BR112019002510A BR112019002510A BR112019002510A2 BR 112019002510 A2 BR112019002510 A2 BR 112019002510A2 BR 112019002510 A BR112019002510 A BR 112019002510A BR 112019002510 A BR112019002510 A BR 112019002510A BR 112019002510 A2 BR112019002510 A2 BR 112019002510A2
- Authority
- BR
- Brazil
- Prior art keywords
- amino acid
- acid sequence
- malignant tumor
- target peptide
- tumor target
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 5
- 150000001413 amino acids Chemical class 0.000 abstract 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4721—Lipocortins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Optics & Photonics (AREA)
- Polymers & Plastics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
a presente invenção fornece um peptídeo compreendendo a sequência de aminoácido representada por qualquer uma das fórmulas (i) a (iii), e um conjugado compreendendo o peptídeo e uma parte funcional. (i) a sequência de aminoácido (x1)[d]p[d](x2)[d] (na sequência, x1 representa w ou f, x2 representa s ou t, e cada símbolo de aminoácido diretamente seguido pelo símbolo [d] representa a forma d do dito aminoácido); (ii) a sequência de aminoácido de p[d]t[d](x)nf[d] (na sequência, (x)n representa n aminoácidos dados selecionados independentemente, n representa um número inteiro de 0 a 4, e o símbolo [d] representa o mesmo como acima); (iii) uma sequência de aminoácido retroinverso de qualquer uma das sequências de aminoácido entre (i) e (ii).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016159743 | 2016-08-16 | ||
PCT/JP2017/030003 WO2018034356A1 (ja) | 2016-08-16 | 2017-08-16 | 悪性腫瘍標的ペプチド |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019002510A2 true BR112019002510A2 (pt) | 2019-06-25 |
Family
ID=61196808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019002510A BR112019002510A2 (pt) | 2016-08-16 | 2017-08-16 | peptídeo alvo de tumor maligno |
Country Status (17)
Country | Link |
---|---|
US (2) | US10695396B2 (pt) |
EP (1) | EP3502122B1 (pt) |
JP (2) | JP6666613B2 (pt) |
KR (1) | KR102422174B1 (pt) |
CN (1) | CN109563128B (pt) |
AU (1) | AU2017311927B2 (pt) |
BR (1) | BR112019002510A2 (pt) |
CA (1) | CA3032775C (pt) |
ES (1) | ES2901232T3 (pt) |
IL (1) | IL264845B2 (pt) |
MX (1) | MX2019001905A (pt) |
PH (1) | PH12019500306A1 (pt) |
PL (1) | PL3502122T3 (pt) |
PT (1) | PT3502122T (pt) |
RU (1) | RU2770197C2 (pt) |
WO (1) | WO2018034356A1 (pt) |
ZA (1) | ZA201901318B (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3502122T3 (pl) * | 2016-08-16 | 2022-02-14 | National Institute Of Advanced Industrial Science And Technology | Peptyd ukierunkowany na złośliwy guz nowotworowy |
JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
EP3811980A4 (en) * | 2018-06-20 | 2022-04-13 | Hirosaki University | BORON ACCUMULATION DRUG 10 FOR NEUTRON CAPTURE THERAPY BY BORON TO SELECTIVELY OR LOCALLY TARGETING TUMOR TISSUES IN SHORT TIME |
JP7224628B2 (ja) * | 2019-02-01 | 2023-02-20 | 国立研究開発法人産業技術総合研究所 | 抗mc16抗体 |
CN113795501A (zh) * | 2019-03-26 | 2021-12-14 | 国立大学法人新潟大学 | 肽及其应用 |
CN113573783A (zh) * | 2019-03-26 | 2021-10-29 | 株式会社岛津制作所 | 光免疫疗法及其使用的药剂 |
KR20220052918A (ko) | 2019-07-10 | 2022-04-28 | 싸이브렉사 2, 인크. | 치료제로서의 사이토톡신의 펩티드 접합체 |
EP3996749A1 (en) | 2019-07-10 | 2022-05-18 | Cybrexa 3, Inc. | Peptide conjugates of microtubule-targeting agents as therapeutics |
CN113372415A (zh) * | 2020-06-18 | 2021-09-10 | 长春理工大学 | 一种人膀胱癌特异性抗原结合肽 |
KR20240086735A (ko) | 2022-11-25 | 2024-06-19 | 이화여자대학교 산학협력단 | 암 표적 펩티드, 이를 포함하는 전구약물 나노입자 및 이를 포함하는 암 예방 또는 치료용 약학적 조성물 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2390075T3 (es) * | 2004-03-19 | 2012-11-06 | Institut Pasteur | Péptidos derivados de la proteína BPLP humana, polinucleótidos que codifican dichos péptidos y anticuerpos dirigidos contra dichos péptidos |
WO2010022444A1 (en) * | 2008-08-25 | 2010-03-04 | The Walter And Eliza Hall Institute Of Medical Research | Methods and agents for modulating kinase signalling pathways through modulation of mixed-lineage kinase domain-like protein (mlkl) |
US9610359B2 (en) * | 2009-12-23 | 2017-04-04 | Burnham Institute For Medical Research | Methods and compositions related to annexin 1-binding compounds |
EP2525820B1 (en) * | 2010-01-19 | 2016-05-11 | Immunomedics, Inc. | Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r) |
WO2015016768A1 (en) * | 2013-07-29 | 2015-02-05 | Temasek Life Sciences Laboratory Limited | Jatropha curcas casbene synthase genes |
JP6036878B2 (ja) | 2015-02-27 | 2016-11-30 | マツダ株式会社 | 四輪駆動車の制御装置 |
PL3502122T3 (pl) * | 2016-08-16 | 2022-02-14 | National Institute Of Advanced Industrial Science And Technology | Peptyd ukierunkowany na złośliwy guz nowotworowy |
CN113573783A (zh) * | 2019-03-26 | 2021-10-29 | 株式会社岛津制作所 | 光免疫疗法及其使用的药剂 |
-
2017
- 2017-08-16 PL PL17841577T patent/PL3502122T3/pl unknown
- 2017-08-16 AU AU2017311927A patent/AU2017311927B2/en active Active
- 2017-08-16 RU RU2019107377A patent/RU2770197C2/ru active
- 2017-08-16 IL IL264845A patent/IL264845B2/en unknown
- 2017-08-16 JP JP2018534447A patent/JP6666613B2/ja active Active
- 2017-08-16 BR BR112019002510A patent/BR112019002510A2/pt unknown
- 2017-08-16 CA CA3032775A patent/CA3032775C/en active Active
- 2017-08-16 US US16/326,120 patent/US10695396B2/en active Active
- 2017-08-16 KR KR1020197005245A patent/KR102422174B1/ko active IP Right Grant
- 2017-08-16 EP EP17841577.4A patent/EP3502122B1/en active Active
- 2017-08-16 PT PT178415774T patent/PT3502122T/pt unknown
- 2017-08-16 WO PCT/JP2017/030003 patent/WO2018034356A1/ja unknown
- 2017-08-16 CN CN201780050376.5A patent/CN109563128B/zh active Active
- 2017-08-16 MX MX2019001905A patent/MX2019001905A/es unknown
- 2017-08-16 ES ES17841577T patent/ES2901232T3/es active Active
-
2019
- 2019-02-13 PH PH12019500306A patent/PH12019500306A1/en unknown
- 2019-03-01 ZA ZA2019/01318A patent/ZA201901318B/en unknown
-
2020
- 2020-02-06 JP JP2020019138A patent/JP2020079288A/ja active Pending
- 2020-06-25 US US16/912,688 patent/US20200323943A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL264845B1 (en) | 2023-05-01 |
EP3502122A1 (en) | 2019-06-26 |
JP2020079288A (ja) | 2020-05-28 |
PL3502122T3 (pl) | 2022-02-14 |
CN109563128B (zh) | 2023-02-28 |
IL264845A (pt) | 2019-03-31 |
MX2019001905A (es) | 2019-05-15 |
CN109563128A (zh) | 2019-04-02 |
US20200323943A1 (en) | 2020-10-15 |
AU2017311927A1 (en) | 2019-03-07 |
RU2770197C2 (ru) | 2022-04-14 |
US20190175684A1 (en) | 2019-06-13 |
CA3032775A1 (en) | 2018-02-22 |
JPWO2018034356A1 (ja) | 2019-08-08 |
KR20190039153A (ko) | 2019-04-10 |
JP6666613B2 (ja) | 2020-03-18 |
ES2901232T3 (es) | 2022-03-21 |
CA3032775C (en) | 2024-01-23 |
AU2017311927B2 (en) | 2021-06-03 |
PH12019500306A1 (en) | 2020-01-20 |
WO2018034356A1 (ja) | 2018-02-22 |
EP3502122B1 (en) | 2021-10-20 |
KR102422174B1 (ko) | 2022-07-18 |
PT3502122T (pt) | 2021-11-25 |
RU2019107377A3 (pt) | 2020-12-17 |
EP3502122A4 (en) | 2020-04-01 |
US10695396B2 (en) | 2020-06-30 |
ZA201901318B (en) | 2020-08-26 |
IL264845B2 (en) | 2023-09-01 |
RU2019107377A (ru) | 2020-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019002510A2 (pt) | peptídeo alvo de tumor maligno | |
PH12020500396A1 (en) | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof | |
AU2018236742B2 (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
CY1119928T1 (el) | Διμερης λειτουργικη συμπληρωματικοτητα επαγομενη απο διττο αντιγονο | |
CO2020001113A2 (es) | Muteínas de interleucina 21 y métodos de tratamiento | |
CY1122074T1 (el) | Νεα παραγωγα 3'-δεοξυαδενοσινης του φωσφοραμαδικου εστερα toy 2' και/η 5' aminoξεος ως αντικαρκινικες ενωσεις | |
BR112018012784A2 (pt) | ácidos nucleicos que codificam as sequências de aminoácido repetitivas ricas em resíduos de prolina e alanina que possuem sequências de nucleotídeo de baixa repetição | |
CY1119219T1 (el) | Anti-ceacam5 αντισωματα και χρησεις αυτων | |
RU2015146614A (ru) | Конъюгированная вакцина на основе пептида антигена wt1 | |
BR112015004501A2 (pt) | derivado de ácido hialurônico tendo aminoácidos e grupos esterila introduzidos no mesmo | |
PH12017501539A1 (en) | Disacetoxytubulysin h and analogs thereof | |
BR112013030253A2 (pt) | compostos com grupos de éster de oxima e/ou acila | |
BR112018077358A2 (pt) | tagatose-6-fosfato fosfatase termoestável inovadora e um método para produzir tagatose com o uso da mesma | |
JOP20200323A1 (ar) | طرق لتصنيع تركيبات الأحماض الأمينية | |
EA201892514A1 (ru) | Промежуточные соединения для синтеза производных желчных кислот, в частности обетихолевой кислоты | |
ATE427117T1 (de) | Verwendung nativer peptide und deren optimierter derivate zur impfung | |
ATE466079T1 (de) | Nukleinsäure konstrukten, pharmazeutische kompositionen und methoden für die behandlung von krebs | |
CY1121859T1 (el) | Μεθοδος παρασκευης αναστολεων συνθασης γλυκοζυλοκεραμιδης | |
BR112018015160A2 (pt) | compostos trisamida e composições compreendendo os mesmos | |
BR112017016883A2 (pt) | compostos com atividade antitumoral | |
AR105397A1 (es) | Método para el tratamiento de las enfermedades de plantas | |
MX2020007393A (es) | Compuestos de fósforo(n)amidatacetal y fosf(on)atalcetal. | |
EA201991702A1 (ru) | Самосборные белковые наночастицы, инкапсулирующие иммуностимулирующие нуклеиновые кислоты | |
EA201891866A1 (ru) | N,N-ДИМЕТИЛ-3-[[5-(3-МЕТИЛ-2-ОКСО-1-ТЕТРАГИДРОПИРАН-4-ИЛ-ИМИДАЗО[4,5-c]ХИНОЛИН-8-ИЛ)-2-ПИРИДИЛ]ОКСИ]ПРОПАН-1-АМИНОКСИД В КАЧЕСТВЕ МОДУЛЯТОРА АТМ-КИНАЗЫ (МУТАЦИИ АТАКСИИ-ТЕЛЕАНГИЭКТАЗИИ) ДЛЯ ЛЕЧЕНИЯ РАКА | |
BR112017021401A2 (pt) | produção de compostos fragrantes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |